Pfizer reveals positive data from Phase 3 trial of ABROCITINIB
Category: #health  | By Mateen Dalal  | Date: 2019-10-14 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Pfizer reveals positive data from Phase 3 trial of ABROCITINIB

Atopic Dermatitis (AD) is a chronic skin disease characterized by skin barrier defects and inflammation. It results in itching, induration (hardening)/papulation (formulation of papules), and oozing/crusting and affects up to 10% of adults and up to 20% of children in the world. Many researchers and pharmaceutical firms are carrying out clinical trials to develop drugs to treat this disease.

Pfizer Inc. is one such organization which has reportedly announced results of its Phase 3, 12-week, pivotal study in patients who are suffering from atopic dermatitis. Abrocitinib, the firm’s investigational JAK1 inhibitor, has shown positive results and has met all key secondary as well as co-primary endpoints in patients aged 12 years and above.

According to the trial’s safety data, both assessed doses of abrocitinib (100mg and 200mg) were well tolerated and are consistent with companion study (JADE MONO-2) from the JADE (JAK1 Atopic Dermatitis Efficacy and Safety) global development program.

Moreover, the number of subjects who achieved each co-primary and secondary efficacy endpoint was statically higher with abrocitinib as compared to placebo by the end of week 12.

Reports cite that the co-primary endpoints of the trial were an IGA (Investigator Global Assessment) score of clear (0) or almost clear (1) skin and two-point or more improvement compared to baseline, and at least a 75% or greater change in their EASI score from baseline.

Furthermore, key secondary endpoints were a four-point or more decrease in itch severity assessed using the pruritus NRS (Numerical Rating Scale), and the magnitude of decrease in the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD).

Apparently, a considerable number of patients showed a response during the first two to four weeks in the dosing period. Both doses were well-tolerated with patients. Moreover, discontinuation rates were noted to be low as compared to placebo.

Michael Corbo, Chief Development Officer, Inflammation & Immunology of Pfizer Global Product Development, stated that there is a vital need for additional treatment options for patients who are suffering from moderate to severe atopic dermatitis. Corbo added that, if the drug is approved, abrocitinib would be the first oral, once daily treatment option for patients.

SourceCredit–https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_positive_phase_3_data_at_the_28th_congress_of_the_european_academy_of_dermatology_and_venereology_for_abrocitinib_in_moderate_to_severe_atopic_dermatitis

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...